SEP 9, 2026 · JOURNAL ARTICLE
Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia
Asm Case Reports
A single immunocompromised patient case report describing off-label dalbavancin use for B. cereus bacteremia; no comparator, no control group, and the authors themselves call for further study.
Reported
Dalbavancin dose1,500 mg intravenous single dose
Time to blood culture clearanceday 5
Follow-up duration90 days